3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big-name players and clinical-stage companies alike.

D&D Pharmatech Announces The Lancet Gastroenterology & Hepatology Publication of Phase 2 Data Demonstrating Rapid, Weight-Independent Activity of Zabopegdutide (DD01) in MASLD/MASH

D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced the publication of 12-week ...

MASH therapy enters a more competitive era

Rezdiffra is no longer the only option; it is the incumbent to beat, and it is being approached from two different ...
Medical Xpress

MASH discovery redefines subtypes with distinct risks: Findings could shape future of fatty liver disease treatment

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease ...